These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 8834896

  • 1. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
    Zoulim F, Dannaoui E, Borel C, Hantz O, Lin TS, Liu SH, Trépo C, Cheng YC.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):448-53. PubMed ID: 8834896
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
    Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trépo C, Cheng YC, Zoulim F.
    Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
    [Abstract] [Full Text] [Related]

  • 3. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
    Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, Cheng YC, Trepo C.
    J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
    [Abstract] [Full Text] [Related]

  • 4. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
    Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer P, Averett DR, Pugh J, Mason WS.
    J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.
    Aguesse-Germon S, Liu SH, Chevallier M, Pichoud C, Jamard C, Borel C, Chu CK, Trépo C, Cheng YC, Zoulim F.
    Antimicrob Agents Chemother; 1998 Feb; 42(2):369-76. PubMed ID: 9527788
    [Abstract] [Full Text] [Related]

  • 6. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
    Seignères B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trépo C, Zoulim F.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
    [Abstract] [Full Text] [Related]

  • 7. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
    [Abstract] [Full Text] [Related]

  • 8. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver.
    Fourel I, Saputelli J, Schaffer P, Mason WS.
    J Virol; 1994 Feb; 68(2):1059-65. PubMed ID: 8289335
    [Abstract] [Full Text] [Related]

  • 9. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
    Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P.
    J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
    Seignères B, Pichoud C, Martin P, Furman P, Trépo C, Zoulim F.
    Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
    [Abstract] [Full Text] [Related]

  • 11. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.
    Mason WS, Cullen J, Saputelli J, Wu TT, Liu C, London WT, Lustbader E, Schaffer P, O'Connell AP, Fourel I.
    Hepatology; 1994 Feb; 19(2):398-411. PubMed ID: 8294097
    [Abstract] [Full Text] [Related]

  • 12. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
    Hu Q, Fang Y, Zhang ZM, Zhang XY, Zhang ZH, Yang DL.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
    [Abstract] [Full Text] [Related]

  • 13. Selective inhibition of the reverse transcription of duck hepatitis B virus by binding of 2',3'-dideoxyguanosine 5'-triphosphate to the viral polymerase.
    Howe AY, Robins MJ, Wilson JS, Tyrrell DL.
    Hepatology; 1996 Jan; 23(1):87-96. PubMed ID: 8550054
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.
    Hafkemeyer P, Keppler-Hafkemeyer A, al Haya MA, von Janta-Lipinski M, Matthes E, Lehmann C, Offensperger WB, Offensperger S, Gerok W, Blum HE.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):792-4. PubMed ID: 8851615
    [Abstract] [Full Text] [Related]

  • 15. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
    Tsiquaye KN, Slomka MJ, Maung M.
    J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
    [Abstract] [Full Text] [Related]

  • 16. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY, Cheng AC, Wang MS, Xu DW, Zeng W, Li Z.
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
    Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC.
    J Med Chem; 1994 Mar 18; 37(6):798-803. PubMed ID: 8145230
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro.
    Schröder I, Holmgren B, Oberg M, Löfgren B.
    Antiviral Res; 1998 Jan 18; 37(1):57-66. PubMed ID: 9497073
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase.
    Kassianides C, Hoofnagle JH, Miller RH, Doo E, Ford H, Broder S, Mitsuya H.
    Gastroenterology; 1989 Nov 18; 97(5):1275-80. PubMed ID: 2477299
    [Abstract] [Full Text] [Related]

  • 20. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.
    Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC.
    Biochem Pharmacol; 1994 Jan 20; 47(2):171-4. PubMed ID: 8304960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.